Mineralys Reports Lorundrostat Trial Results
The experimental blood pressure drug showed efficacy in two trials but failed to treat obstructive sleep apnea.
Updated on Oct. 15, 2026 in Heart Disease
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their drug development goals?
Mineralys Therapeutics recently reported clinical trial results for its experimental aldosterone synthase inhibitor, lorundrostat. While the drug significantly lowered blood pressure in participants, it did not demonstrate a measurable impact on obstructive sleep apnea.
Why it matters
The studies aim to provide a new treatment option for patients struggling with uncontrolled or treatment-resistant hypertension. Establishing the efficacy of this drug is a critical step in addressing high blood pressure populations.
In the Explore-OSA trial, patients receiving 50 milligrams of lorundrostat saw an average morning systolic blood pressure reduction of 11.1 mmHg compared to just 1.0 mmHg in the placebo group. The Launch-HTN trial found that 46% of participants reached a target systolic blood pressure below 130 mmHg.
The players
Mineralys Therapeutics
This clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, focuses on developing treatments for diseases driven by dysregulated aldosterone.
William Harvey Heart Centre
Located in London, this research facility is internationally recognized for its work in cardiovascular medicine and clinical heart research.
The details
Lorundrostat functions by targeting the CYP11B2 enzyme to inhibit aldosterone synthase, which helps regulate blood pressure. Despite these cardiovascular gains, the Explore-OSA trial showed no measurable change in the apnea-hypopnea index, failing to improve obstructive sleep apnea symptoms.
Timeline
The American Heart Association Hypertension Scientific Sessions occurred in 2026.
The Big Picture
This research builds upon the scientific understanding of the CYP11B2 enzyme inhibition pathway as a viable target for blood pressure management. The findings represent a notable step in verifying that blocking aldosterone production can effectively lower systolic pressure where other treatments have historically struggled.
If approved, lorundrostat could provide a new daily treatment option for patients with treatment-resistant hypertension who have not seen success with standard therapies. Patients should consult their doctors about how evolving clinical results may eventually affect future hypertension care plans.
The takeaway
While lorundrostat shows promise for lowering blood pressure, it is not a cure for obstructive sleep apnea. Patients should continue adhering to current medical guidelines for hypertension management until further clinical data is available.
Further reading
For more information on cardiovascular research, visit Heart Disease.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their drug development goals?
